Welcome to our dedicated page for Talphera SEC filings (Ticker: tlph), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Talphera’s drug-development disclosures can feel like navigating a medical journal. Each 10-K details nafamostat pharmacology, clinical-trial costs, and cash runway forecasts—vital yet deeply technical. Add 8-K notices on FDA Breakthrough Device designations and you have a stack of documents few investors can finish. That’s why Stock Titan pairs Talphera’s complete SEC feed with AI-powered summaries that translate chemistry jargon into actionable data.
Use our platform to answer the questions people actually ask: “Where is Talphera’s quarterly earnings report 10-Q filing?” or “How do I track Talphera insider trading Form 4 transactions?” We surface every form the moment it hits EDGAR—10-K annual reports, 10-Q quarterlies, 8-K material events, S-1 offerings, and definitive proxy statements. Want specifics? The 10-K section on R&D spend is linked to charts, Form 4 insider transactions real-time alerts flag when executives buy shares before NEPHRO study results, and proxy statement executive compensation tables are distilled into clear comparisons.
Here’s how it helps you work faster:
- AI-generated overviews that make Talphera SEC filings explained simply
- Real-time e-mail or SMS when a new Talphera 8-K material events explained filing appears
- Side-by-side earnings report filing analysis for sequential trial spending trends
- Clickable links to Talphera annual report 10-K simplified, plus understanding Talphera SEC documents with AI video guides
- Filters for Talphera executive stock transactions Form 4 and historical option grants
Whether you monitor dilution risk ahead of a secondary offering or compare quarter-over-quarter burn rates, Stock Titan supplies every disclosure—clarified, organized, and always current.
Talphera, Inc. is advancing nafamostat-based product candidates and is funded through recent equity financings. The company reports 200,000,000 shares authorized and 20,522,655 shares issued and outstanding as of June 30, 2025, up from 17,029,469 at December 31, 2024. Its lead developmental product, Niyad, a lyophilized formulation of nafamostat, is being studied under an IDE and has received FDA Breakthrough Device Designation for regional anticoagulation in continuous renal replacement therapy; nafamostat is approved in Japan and South Korea for related uses. Talphera also acquired LTX-608, a nafamostat IV formulation for potential ARDS, DIC, acute pancreatitis or antiviral use. A securities appeal remains pending after dismissal of plaintiffs’ case; briefing completed January 21, 2025 and oral argument occurred June 12, 2025. The company completed a private placement that included 4,999,316 pre-funded warrants exercisable at $0.001 and other financing activity disclosed.
Talphera, Inc. (TLPH) furnished a press release on August 14, 2025 announcing its financial results for the three months ended June 30, 2025 and providing a corporate update. The Form 8-K states the press release is included as Exhibit 99.1 and clarifies the information is being "furnished" rather than "filed," so it is not subject to Section 18 liability under the Exchange Act and is not incorporated by reference into other filings except by specific reference. No financial figures or operational details are included in the 8-K itself; readers are directed to the referenced press release for the substantive results.
FAQ
What is the current stock price of Talphera (tlph)?
What is the market cap of Talphera (tlph)?
